

Apollo Life Sciences Limited (ASX: AOP)



Apollo Life Sciences Limited is an Australian-based innovative biotechnology company focused on improving drug delivery methods of accepted protein and antibody based therapeutics.

The Company has developed and patented two major needle-free technologies, the oral Oradel™ platform and the transdermal Intradel™ platform, designed to eliminate patients' discomfort, improve effectiveness and lower the cost of therapeutics in major biopharmaceutical market segments. Entering clinical development are two applications of the Oradel™ platform: insulin tablets for the \$18 billion per annum diabetes market and a proprietary TNF blocker for the \$10 billion arthritis market, as well as a product based on the Intradel™ platform: a topical cream for the \$5 billion psoriasis market.

In general, Oradel™ allows the uptake of large molecule proteins and antibodies in an active form, from the stomach into the bloodstream, through the use of small molecule transporters, protecting the compounds from stomach enzymes. Intradel™ works by delivering a protein-laden water layer across the skin and into the surrounding dermal and sub-dermal layers, overturning the long-held view that large water or oil soluble molecules, cannot penetrate the skin.

The company has also created a library of over eighty recombinant human cell derived (hcx™) proteins that provide a rich source of candidate biopharmaceuticals to treat a wide range of diseases and is also increasingly employed for research and diagnostic testing.

CURRENT PRICE: A\$0.36
52-WEEK RANGE: A\$0.30 - A\$0.56
AVG DAILY VOLUME (90-DAY): 166,318
OUTSTANDING SHARES: 97.9 million
MARKET CAPITALIZATION: A\$35.2 million

INCOME STATEMENT HIGHLIGHTS

REVENUE: A\$0.5 million
EBITDA: (A\$8.6 million)
NET INCOME: (A\$8.4 million)
EPS (Diluted): (A\$0.04)

All figures twelve months trailing as of December 31, 2006

BALANCE SHEET HIGHLIGHTS

CASH & EQUIVALENTS: A\$10.5 million
WORKING CAPITAL: A\$9.9 million
TOTAL ASSETS: A\$11.9 million
NET WORTH: A\$9.6 million

All figures as of December 31, 2006

RECENT NEWS HEADLINES

Mon, Apr 30, 2007


Apollo Life Sciences has released results of preliminary trials of its patented needle-free vaccine technology, which showed that it can successfully deliver tetanus toxoid vaccine directly through the skin of mice. The technology has the potential to be applied in the delivery of influenza and measles-mumps-rubella vaccines that are given to Australian children. Apollo expects to begin human trials of the technology later this year.

Thu, Apr 5, 2007

Apollo Life Sciences raised A\$3,580,000 through the combined private placement and share purchase plan at A\$0.42. The capital will be used primarily to assist in funding human trials of oral insulin and the recently announced oral TNF blocker for arthritis. Apollo has made strong progress with preclinical efficacy and safety studies for oral insulin and is now positioned to enter human clinical trials.

HEADQUARTERS

Apollo Life Science Limited
 147 Queen Street, Beaconsfield
 Sydney NSW 2015
 Phone: +61 2 9310 1800 Fax: +61 2 9699 8615
 Web Site: www.apollolifescience.com
 Email: contact@apollolifescience.com



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to its accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Flaherty Financial News / WallStreet Research Small Cap Conference Book or the www.WallStreetResearch.org website.